Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Hallmarks and Signaling of Cancer Cells. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Hallmarks and Signaling of Cancer Cells (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 111 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Drug Repurposing - Old Drugs, New Tricks

Drug repurposing, also called drug repositioning, is the process of screening existing libraries of drugs already approved by the FDA in an effort to identify compounds that are effective in other diseases.
According to F. Bertolini et al., in a report on oncology drug sales and expenditure, the year 2013 saw $43 billion in sales from the 10-big oncology drug makers and $91 billion spent on drug development.
A concerted effort by pharmaceutical companies and academic core facilities has led to quite a few successfully repurposed drugs (Table 1).
Advantages of repurposing existing drugs include:
  1. Considerably reduced time for research and development and for FDA approval
  2. Availability of safety and toxicity profiles that have been tested for decades
  3. Unmatched fiscal considerations in off-patent drugs
A summary is provided in Table 2.
A twist on drug repurposing and outcomes is the story of rare disorders and associated orphan drugs. Rare disorders are illnesses of low prevalence with very small populations of patients. Drugs for rare disease treatment are termed as "orphan drugs." To provide incentives to the pharmaceutical industry to produce orphan drugs, the United States congress passed Orphan Drug Act in the U.S. in 1983. Despite low demand, orphan drugs can yield high profit with hefty prices. These, along with the subsidies, tax credits, and waivers, have turned certain orphan drugs into blockbuster drugs. For example, Pulmozyme is an orphan drug used for cystic fibrosis treatment that has increased life expectancy for individuals with cystic fibrosis from their teens to their forties even fifties.